Background d
Despitee several advances in our basic understanding and in the clinical management of pancreatic cancer, virtuallyy all patients who will be diagnosed with pancreatic cancer will die from this disease. The high mortalityy of pancreatic cancer is predominantly because of diagnosis at an advanced stage of disease and aa lack of effective treatments. We used the Gene Logic Inc. BioExpress platform and Affymetrix GeneChip arrayss to identify genes differentially expressed in pancreatic cancer.
Methods s
cDNAA was prepared from samples of normal pancreas (n=11), normal gastrointestinal mucosa (n=22), resectedd pancreas cancer tissues (n=14), and pancreas cancer cell lines (n=8), and was hybridized to the completee Affymetrix Human Genome U95 GeneChip set (arrays U95 A, B, C, D, and E) for simultaneous analysiss of 60,000 cDNA fragments, with 12,000 fragments covering full-length genes and 48,000 fragmentss covering expressed sequence tags (ESTs) . Genes expressed at levels at least fivefold greater in thee pancreatic cancers as compared to normal tissues were identified. Serial analysis of gene expression (SAGE)) libraries (http://www.ncbi.nlm.nih.gov/SAGE/) of two normal pancreatic ductal cell cultures (HX andd H126) were used to exclude genes expressed in the normal ducts (more than five tags per library).
Differentiall expression of selected candidate genes was validated by immunohistochemical analysis (n=3), byy in situ hybridization (n=1), and by reverse transcriptase-polymerase chain reaction (n=8).
Results s
Onee hundred eighty fragments were identified as having fivefold or greater expression levels in pancreas cancerr specimens as compared to normal tissue, of which 124 corresponded to known genes and 56 to ESTs.. Of these 124 fragments, 10 genes were represented by two or more fragments, resulting in 107 knownn genes identified as differentially expressed in pancreatic cancer. An additional 10 genes were expressedd in the SAGE libraries of normal pancreatic duct epithelium, and were excluded from further analysis.. A literature search indicated that 28 of the remaining 97 genes have been reported in association withh pancreatic cancer, validating this approach. The remaining 69 genes have not been implicated in pancreaticc cancer before.
Conclusions s
Usingg global gene expression technology 97 differentially expressed genes in infiltrating pancreatic cancer weree identified. These genes provide insights into the biology of pancreatic cancer and might have immediatee potential as novel therapeutic targets and tumor markers. Pancreaticc cancer continues to have one of the highest mortality rates of any malignancy. Each year,, 28,000 patients are diagnosed with pancreatic cancer, and nearly 28,000 will die of their disease. 11 The vast majority of patients are diagnosed at an advanced stage of disease because currentlyy no tumor markers are known that allow reliable screening for pancreatic cancer at an earlier,, potentially curative stage. This is a particular problem for those patients with a strong $ familiall history of pancreatic cancer, who may have up to a 57-fold greater risk of developing "S pancreaticc cancer in their lifetime/' New tumor markers of pancreatic cancer are urgently needed. w
Thee utility of RNA-based global gene expression profiling biotechniques in identifying new markers off cancer is established. 3 - 4 For example, we have identified two new potential markers of pancreatic carcinoma,, mesothelin and prostate stem cell antigen, using serial analysis of gene expression n (SAGE). 566 Both markers are expressed specifically by the neoplastic epithelium of infiltrating § carcinomass of the pancreas as compared to normal duct epithelium, and both offer new possibilities * forr the development of screening markers and therapeutic targets. » (0 0
InIn an effort to identify additional potential markers of pancreatic carcinoma, we used the Gene " § n n Logicc Inc. Bio-Express platform and Affymetrix GeneChip arrays to identify genes differentially K o o expressedd in a large series of pancreatic cancers. Biocomputational tools were used to determine J in n thosee genes most highly expressed within pancreatic cancer samples compared to normal pancreatic 3-tissue.. Genes found to be significantly expressed in SAGE libraries of normal pancreatic ductal cells g* ua a weree excluded, and the expression of selected genes was confirmed by immunohistochemical f.
3 3 labeling,, in situ hybridization and reverse transcriptase-polymerase chain reaction (RT-PCR). Here "g wee report 97 genes differentially overexpressed in pancreatic cancer, 69 of which are novel. 5
Tissues s Sampless (0.5 g) of normal pancreas (n=11); normal duodenal, jejunal, or colonic mucosa (n=22); orr infiltrating pancreatic adenocarcinoma (n=14) were collected from surgical specimens from patientss at The Johns Hopkins Hospital. In each case, the specimens were harvested within 10 minutess of resection from the patient and snap-frozen in liquid nitrogen before storage at .
Thee resected cancers were not microdissected because we were interested in not only identifying thee genes expressed by neoplastic epithelial calls, but also the genes expressed as a result of the neoplasticc cell-stroma interaction. Hematoxylin and eosin-stained sections of adjacent sections of thee tissue were prepared before snap-freezing to confirm the diagnosis. The neoplastic cellularity off these tissue samples ranged from 5 to 55%. Normal gastrointestinal mucosa was included in thee analyses to facilitate the identification of markers of pancreatic cancer that would be useful inn screening secondary sources, such as in duodenal fluid samples. 
InIn situ hybridization
Preparationn of digoxigenin-labeled sense and antisense riboprobes and in situ hybridization were performedd as previously described in detail.' Dataa filtering RNAA samples were hybridized to the complete Affymetrix Human Genome U95 GeneChip set (arrayss U95 A, B, C, D, and E) for simultaneous analysis of 60,000 fragments, with 12,000 fragments coveringg full-length genes and 48,000 fragments covering ESTs. Affymetrix GeneChips were analyzed forr ail genes with a fivefold or greater increase in expression in the pancreatic adenocarcinoma tumorr tissues or cell lines compared to all normal tissues, using a 95% confidence limit. We identified 1800 fragments expressed at least fivefold greater in pancreatic cancer samples as compared to normall tissues, 12 of which were expressed greater than 10-fold. The level of significance for each genee fragment ranged from less than p=0.00001 to p=0.01 (modified Welch (test).
Identificationn of highly expressed genes in pancreatic cancer
Characterizationn of the 180 fragments identified revealed that 56 fragments corresponded to ESTs,, and 124 fragments corresponded to known genes. Among these 124 fragments, 10 genes weree represented by two or more fragments, resulting in 107 known genes identified as expressed att least fivefold or greater in pancreatic cancers as compared to normal (table 1) .
Thee GeneExpress platform allows for an e-Northern analysis of Affymetrix fragments to estimate thee levels of expression of any fragment among the normal and cancer samples analyzed. An e-Northernn was then generated for each of the 124 Affymetrix fragments to determine levels of expressionn of each fragment within the normal tissues, pancreas cancer cell lines, and pancreas cancerr tumor tissues studied. Two prominent patterns of expression were identified (figure 1). Literaturee search of genes highly expressed in pancreatic cancer Forr each of the 97 genes identified, a search was performed using the online NCBi database PubMedd using the known gene name together with the terms "pancreas" or "pancreas cancer."
Off the 97 genes analyzed, 28 genes were previously reported to be associated with pancreatic cancer,, whereas 69 genes were not ( 17 The cellular localization of the corresponding gene productss was aiso determined using the online database OMIM available through the NCBI web sitee {http://www.ncbi.nlm.nih.gov/entrez/query). Genes were found to encode membrane-bound proteinss {prostate stem cell antigen, OB-cadherin), cytoplasmic proteins (fascin, ATDC), nuclear proteinss (topoisomerase lla, paraneoplastic antigen MA1), as well as extracellular proteins, such ass those involved in extracellular matrix homeostasis (hsp47, thrombospondin 2) or secreted proteinn products (osteopontin).
Verificationn of selected candidate tumor markers
Candidatee genes were selected for verification of expression in samples of pancreatic cancer tissuess or cell lines (figures 2 and 3). Four genes were selected for analysis by immunohistochemical orr in situ hybridization techniques: fascin, topoisomerase lla, hsp47, and pleckstrin.
Fascinn and topoisomerase II both showed an A pattern of expression on e-Northern, corresponding too elevated expression in both the resected neoplastic tissues and cancer cell lines.
Immunohistochemicall labeling of fascin showed intensely positive cytoplasmic labeling of the neoplasticc epithelium in eight of eight samples of paraffin-embedded pancreatic duct adenocarcinomass studied (100%). In all cases, normal duct epithelium and desmoplastic stroma didd not express fascin protein ( figure 2A ). Figuree 1 e-Northern analysis of highly expressedd Affymetrix gene fragments identifiedd by the GeneExpress platform. (A)) Affymetrix fragment for sea urchin fascinn homolog, highly expressed in both pancreass cancer cell lines and tumor tissues comparedd to normal (A pattern). (B)) Affymetrix fragment for heat shock proteinn 47, specifically overexpressed in pancreass cancer tumor tissues but not pancreass cancer cell lines or normal tissues (BB pattern).
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Topoisomerasee Hot showed strong positive nuclear immunolabeling within eight of eight pancreatic ductt adenocarcinomas studied (100%). Normal duct epithelium and the surrounding desmoplastic stromaa did not express detectable levels of topoisomerase Ha (figure 2B).
InIn contrast to fascin and topoisomerase Ilex, hsp47 showed a B pattern of expression on e-Northern, indicatingg elevated expression of hsp47 in the resected neoplastic tissues only, but not in the cancerr cell lines or normal tissues ( figure 2C ). In concordance with this pattern, immunolabeling forr hsp47 showed strong labeling of the desmoplastic stroma within the invasive cancer in eight off eight pancreatic duct adenocarcinomas studied (100%). In one of the eight cases, the neoplastic epitheliumm also labeled. No expression of hsp47 was detected within normal pancreatic duct epitheliumm or within the intralobular stroma of normal pancreas tissue within the same paraffinembeddedd tissue sections.
Pleckstrinn was also identified as differentially expressed in pancreatic cancer and displayed an A patternn of expression by e-Northern. No commercially available antibody for pleckstrin was available.. Therefore, a digoxigenin-labeled probe was generated to match the coding region of thee pleckstrin gene for use in in situ hybridization. In situ hybridization using the anti-sense probe showedd expression within the neoplastic epithelium in all eight cases (100%), seen as variably sizedd granules throughout the cytoplasm of the neoplastic epithelium, in contrast to normal duct epitheliumm or the surrounding desmoplastic stroma, which did not express this gene ( figure 3D ) Thee 5-year-survival rate of patients with ductal adenocarcinoma of the pancreas is 4%, one of the lowestt of any neoplasm/ Unfortunately, most patients are diagnosed at an advanced stage of diseasee that is incurable with existing therapy. Thesee 97 differentially expressed markers of pancreatic cancer also have potential for the developmentt of new screening tests for pancreatic cancer. For example, the development of taggedd antibodies to one or more of these genes may be useful in the diagnostic radiological imagingg of small primary pancreatic cancers or metastases before they become clinically apparent.
Severall of these genes were found to be membranous or secreted proteins, suggesting they may bee shed into the blood or pancreatic secretions. If so, these proteins may also serve as diagnostic markerss in such specimens, not only for identification of primary pancreatic cancers at an earlier stage,, but also for the identification of recurrent disease at an earlier phase when it may be more responsivee to adjuvant therapies. In addition, whereas use of any one marker individually may havee a limited sensitivity or specificity in detecting pancreatic cancer, the development of a panel off markers may significantly increase the specificity of detecting clinically inapparent pancreatic cancerss without decreasing the sensitivity. 28 Thee identification of these differentially expressed genes in pancreatic cancer also has important therapeuticc applications for pancreatic cancer. For example, Jaffee and colleagues 75 have recently shownn that cell-mediated immunotherapy can be both safe and effective in patients with pancreatic cancer,, and each of the differentially expressed genes represents a potential target for the developmentt of a ceil-mediated vaccine. Similarly, as a number of the genes identified were found too encode for cell surface proteins (i.e. OB-cadherin, CD83, claudin 1, prostate stem cell antigen, andd retinoic acid-induced 3), these proteins hold promise for the development of antibody-based immunotherapyy against pancreatic carcinoma. cancerss may therefore contribute to the radioresistance often observed for this tumor type. 32 Cheimotherapeuticc resistance in pancreatic cancers may also, in part, be contributed to by genes suchh as TOP2A or TGM2.
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TOP2A is a target for several chemotherapeutic agents, including doxorubicin,, that have been used for treatment of advanced pancreatic cancer. 33 The high levels off TOP2A expression in some pancreatic cancers might indicate amplification of this gene, an occurrencee that contributes to the ineffectiveness of this chemotherapeutic agent in other tumor types."-333 Similarly, the overexpression of TGM2 has also been associated with drug resistance. 34 Otherr highly expressed genes in pancreatic cancer, such as interleukin-8 (IL-8) or the AML1 oncogene,, may contribute to the aggressiveness of this tumor by alternative mechanisms. IL-8 overexpressionn in pancreatic cancers is thought to result from low oxygen tension and hypoxia of thee tumor microenvironment. Consequently, IL-8 overexpression is thought to contribute to the aggressivenesss of pancreatic cancer by inducing angiogenesis and promoting tumor metastasis. 35 Thee AML1 oncogene is a transcription factor that is commonly overexpressed by translocation in acutee myeloid leukemias.
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The overexpression of AML1 in pancreatic cancer suggests that this genee may also play a role in the pathogenesis of this tumor type. Thus, our finding of differentially expressedd genes related to the aggressiveness of pancreatic cancers may be used to develop moree effective therapeutic protocols for this tumor type. 
